Human methylenetetrahydrofolate reductase pharmacogenomics: Gene resequencing and functional genomics

Yvette N. Martin, Oreste E. Salavaggione, Bruce W. Eckloff, Eric D Wieben, Daniel J Schaid, Richard M Weinshilboum

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

5,10-Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme in the folate metabolic pathway. Common genetic polymorphisms in the human MTHFR gene are associated with individual variation in the efficacy and toxicity of chemotherapeutic agents, such as methotrexate and 5-fluorouracil. However, the full range of polymorphisms and intragene haplotypes in the human MTHFR gene remains unclear. Furthermore, cellular mechanisms by which common, naturally occurring nonsynonymous coding single nucleotide polymorphisms (cSNPs) might alter the function of this enzyme have not been defined. The present study focused on the systematic identification and investigation of common polymorphisms and haplotypes in the MTHFR gene using a genotype-to-phenotype strategy, followed by functional genomic studies. Specifically, we resequenced exons, splice junctions and portions of the 5′-flanking region (5′-FR) of the human MTHFR gene using 240 DNA samples from four ethnic groups. A total of 65 polymorphisms were observed, 11 of which were non-synonymous cSNPs. We then performed functional genomic studies with constructs for wild-type and 15 variant allozymes (some with multiple alterations in amino acid sequence) using a mammalian expression system. Activity for the variant allozymes ranged from 13% to 149% of wild-type activity. Levels of immunoreactive protein for the allozymes ranged from 31% to 120% of wild-type and were significantly correlated with enzyme activity (R p = 0.85, P<0.0001), suggesting that a major mechanism by which nonsynonymous cSNPs influence the function of this gene is by alteration in the quantity of protein. These observations represent steps towards an understanding of molecular genetic mechanisms responsible for variation in MTHFR function that may contribute to individual differences in drug efficacy and toxicity, as well as disease risk.

Original languageEnglish (US)
Pages (from-to)265-277
Number of pages13
JournalPharmacogenetics and Genomics
Volume16
Issue number4
StatePublished - Apr 2006

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Pharmacogenetics
Genomics
Isoenzymes
Single Nucleotide Polymorphism
Genes
Haplotypes
Enzymes
5' Flanking Region
Genetic Polymorphisms
Metabolic Networks and Pathways
Drug-Related Side Effects and Adverse Reactions
Folic Acid
Ethnic Groups
Individuality
Methotrexate
Fluorouracil
Molecular Biology
Amino Acid Sequence
Exons

Keywords

  • Gene resequencing
  • Haplotypes
  • MTHFR
  • Nonsynonymous cSNPs
  • Polymorphisms

ASJC Scopus subject areas

  • Genetics
  • Pharmacology

Cite this

Human methylenetetrahydrofolate reductase pharmacogenomics : Gene resequencing and functional genomics. / Martin, Yvette N.; Salavaggione, Oreste E.; Eckloff, Bruce W.; Wieben, Eric D; Schaid, Daniel J; Weinshilboum, Richard M.

In: Pharmacogenetics and Genomics, Vol. 16, No. 4, 04.2006, p. 265-277.

Research output: Contribution to journalArticle

@article{4e2e114b105749f3ad4c01516abf3802,
title = "Human methylenetetrahydrofolate reductase pharmacogenomics: Gene resequencing and functional genomics",
abstract = "5,10-Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme in the folate metabolic pathway. Common genetic polymorphisms in the human MTHFR gene are associated with individual variation in the efficacy and toxicity of chemotherapeutic agents, such as methotrexate and 5-fluorouracil. However, the full range of polymorphisms and intragene haplotypes in the human MTHFR gene remains unclear. Furthermore, cellular mechanisms by which common, naturally occurring nonsynonymous coding single nucleotide polymorphisms (cSNPs) might alter the function of this enzyme have not been defined. The present study focused on the systematic identification and investigation of common polymorphisms and haplotypes in the MTHFR gene using a genotype-to-phenotype strategy, followed by functional genomic studies. Specifically, we resequenced exons, splice junctions and portions of the 5′-flanking region (5′-FR) of the human MTHFR gene using 240 DNA samples from four ethnic groups. A total of 65 polymorphisms were observed, 11 of which were non-synonymous cSNPs. We then performed functional genomic studies with constructs for wild-type and 15 variant allozymes (some with multiple alterations in amino acid sequence) using a mammalian expression system. Activity for the variant allozymes ranged from 13{\%} to 149{\%} of wild-type activity. Levels of immunoreactive protein for the allozymes ranged from 31{\%} to 120{\%} of wild-type and were significantly correlated with enzyme activity (R p = 0.85, P<0.0001), suggesting that a major mechanism by which nonsynonymous cSNPs influence the function of this gene is by alteration in the quantity of protein. These observations represent steps towards an understanding of molecular genetic mechanisms responsible for variation in MTHFR function that may contribute to individual differences in drug efficacy and toxicity, as well as disease risk.",
keywords = "Gene resequencing, Haplotypes, MTHFR, Nonsynonymous cSNPs, Polymorphisms",
author = "Martin, {Yvette N.} and Salavaggione, {Oreste E.} and Eckloff, {Bruce W.} and Wieben, {Eric D} and Schaid, {Daniel J} and Weinshilboum, {Richard M}",
year = "2006",
month = "4",
language = "English (US)",
volume = "16",
pages = "265--277",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Human methylenetetrahydrofolate reductase pharmacogenomics

T2 - Gene resequencing and functional genomics

AU - Martin, Yvette N.

AU - Salavaggione, Oreste E.

AU - Eckloff, Bruce W.

AU - Wieben, Eric D

AU - Schaid, Daniel J

AU - Weinshilboum, Richard M

PY - 2006/4

Y1 - 2006/4

N2 - 5,10-Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme in the folate metabolic pathway. Common genetic polymorphisms in the human MTHFR gene are associated with individual variation in the efficacy and toxicity of chemotherapeutic agents, such as methotrexate and 5-fluorouracil. However, the full range of polymorphisms and intragene haplotypes in the human MTHFR gene remains unclear. Furthermore, cellular mechanisms by which common, naturally occurring nonsynonymous coding single nucleotide polymorphisms (cSNPs) might alter the function of this enzyme have not been defined. The present study focused on the systematic identification and investigation of common polymorphisms and haplotypes in the MTHFR gene using a genotype-to-phenotype strategy, followed by functional genomic studies. Specifically, we resequenced exons, splice junctions and portions of the 5′-flanking region (5′-FR) of the human MTHFR gene using 240 DNA samples from four ethnic groups. A total of 65 polymorphisms were observed, 11 of which were non-synonymous cSNPs. We then performed functional genomic studies with constructs for wild-type and 15 variant allozymes (some with multiple alterations in amino acid sequence) using a mammalian expression system. Activity for the variant allozymes ranged from 13% to 149% of wild-type activity. Levels of immunoreactive protein for the allozymes ranged from 31% to 120% of wild-type and were significantly correlated with enzyme activity (R p = 0.85, P<0.0001), suggesting that a major mechanism by which nonsynonymous cSNPs influence the function of this gene is by alteration in the quantity of protein. These observations represent steps towards an understanding of molecular genetic mechanisms responsible for variation in MTHFR function that may contribute to individual differences in drug efficacy and toxicity, as well as disease risk.

AB - 5,10-Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme in the folate metabolic pathway. Common genetic polymorphisms in the human MTHFR gene are associated with individual variation in the efficacy and toxicity of chemotherapeutic agents, such as methotrexate and 5-fluorouracil. However, the full range of polymorphisms and intragene haplotypes in the human MTHFR gene remains unclear. Furthermore, cellular mechanisms by which common, naturally occurring nonsynonymous coding single nucleotide polymorphisms (cSNPs) might alter the function of this enzyme have not been defined. The present study focused on the systematic identification and investigation of common polymorphisms and haplotypes in the MTHFR gene using a genotype-to-phenotype strategy, followed by functional genomic studies. Specifically, we resequenced exons, splice junctions and portions of the 5′-flanking region (5′-FR) of the human MTHFR gene using 240 DNA samples from four ethnic groups. A total of 65 polymorphisms were observed, 11 of which were non-synonymous cSNPs. We then performed functional genomic studies with constructs for wild-type and 15 variant allozymes (some with multiple alterations in amino acid sequence) using a mammalian expression system. Activity for the variant allozymes ranged from 13% to 149% of wild-type activity. Levels of immunoreactive protein for the allozymes ranged from 31% to 120% of wild-type and were significantly correlated with enzyme activity (R p = 0.85, P<0.0001), suggesting that a major mechanism by which nonsynonymous cSNPs influence the function of this gene is by alteration in the quantity of protein. These observations represent steps towards an understanding of molecular genetic mechanisms responsible for variation in MTHFR function that may contribute to individual differences in drug efficacy and toxicity, as well as disease risk.

KW - Gene resequencing

KW - Haplotypes

KW - MTHFR

KW - Nonsynonymous cSNPs

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=33645081745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645081745&partnerID=8YFLogxK

M3 - Article

C2 - 16538173

AN - SCOPUS:33645081745

VL - 16

SP - 265

EP - 277

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 4

ER -